Clinical Trial Update: Expanded Access Program for Avapritinib

View source ↗

Summary

Expanded Access Program for Avapritinib has ended and is no longer available for patients with solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Avapritinib (avapritinib)

Snippet

Sponsor: Blueprint Medicines Corporation | Conditions: Solid Tumors | Status: NO_LONGER_AVAILABLE